Metal-based antitumour drugs in the post-genomic era: what comes next?

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Dalton Transactions

• Publication date

  2011-09-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1039/c1dt10522aPMID 21725573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core.

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• A bifunctional organometallic ruthenium drug with multiple modes of inducing apoptosis

  2011cited by this paper
• Gold(III) porphyrin 1a inhibited nasopharyngeal carcinoma metastasis in vivo and inhibited cell migration and invasion in vitro.

  2010cited by this paper
• The X‐ray Structure of the Adduct between NAMI‐A and Carbonic Anhydrase Provides Insights into the Reactivity of this Metallodrug with Proteins

  2010cited by this paper
• The status of platinum anticancer drugs in the clinic and in clinical trials.

  2010cited by this paper
• Organometallic Antitumour Agents with Alternative Modes of Action

  2010cited by this paper
• Iridium complex with antiangiogenic properties.

  2010cited by this paper
• Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

  2010cited by this paper
• Organometallics as Structural Scaffolds for Enzyme Inhibitor Design

  2010cited by this paper
• Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.

  2010cited by this paper
• A gold(III) porphyrin complex with antitumor properties targets the Wnt/beta-catenin pathway.

  2010cited by this paper
• Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.

  2010cited by this paper
• Selenium- and tellurium-containing multifunctional redox agents as biochemical redox modulators with selective cytotoxicity.

  2010cited by this paper
• Recent advances in cancer therapy: an overview.

  2010cited by this paper
• Inhibition of tumor proteasome activity by gold–dithiocarbamato complexes via both redox‐dependent and ‐independent processes

  2010cited by this paper
• The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer.

  2010cited by this paper
• Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer

  2010cited by this paper
• Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.

  2010cited by this paper
• miR-181a and miR-630 regulate cisplatin-induced cancer cell death.

  2010cited by this paper
• Cancer stemness and metastasis: therapeutic consequences and perspectives.

  2010cited by this paper
• Novel cis- and trans-configured bis(oxime)platinum(II) complexes: synthesis, characterization, and cytotoxic activity.

  2010cited by this paper
• Metal complexes in medicine with a focus on enzyme inhibition.

  2010cited by this paper
• Epigenetics in cancer: Targeting chromatin modifications

  2009cited by this paper
• Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.

  2009cited by this paper
• Bioorganometallic chemistry--from teaching paradigms to medicinal applications.

  2009cited by this paper
• Rational design of an organometallic glutathione transferase inhibitor.

  2009cited by this paper
• Inhibition of Schistosoma mansoni Thioredoxin-glutathione Reductase by Auranofin

  2009cited by this paper
• From cisplatin to photoreactive Ru complexes: targeting DNA for biomedical applications

  2009cited by this paper
• Platinum(II) complexes with dipyridophenazine ligands as human telomerase inhibitors and luminescent probes for G-quadruplex DNA.

  2009cited by this paper
• Stabilization of G-quadruplex DNA with platinum(II) Schiff base complexes: luminescent probe and down-regulation of c-myc oncogene expression.

  2009cited by this paper
• Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer.

  2009cited by this paper
• Gold (III) porphyrin complexes induce apoptosis and cell cycle arrest and inhibit tumor growth in colon cancer

  2009cited by this paper
• Role of chemokines and their receptors in cancer.

  2009cited by this paper
• DNA Vaccine Against Tumor Endothelial Marker 8 Inhibits Tumor Angiogenesis and Growth

  2009cited by this paper
• Combined effect of rapamycin and cisplatin on survival of Hep-2 cells in vitro.

  2009cited by this paper
• Terpyridine-platinum(II) complexes are effective inhibitors of mammalian topoisomerases and human thioredoxin reductase 1.

  2009cited by this paper
• Regulation of human carbonic anhydrase I (hCAI) activity by using a photochromic inhibitor.

  2008cited by this paper
• Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.

  2008cited by this paper
• Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

  2008cited by this paper
• The Hsp90 molecular chaperone: an open and shut case for treatment.

  2008cited by this paper
• Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways.

  2008cited by this paper
• Medical treatment of advanced testicular cancer.

  2008cited by this paper
• 210 POSTER Preliminary results of a Phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing first-line therapy for colorectal cancer (CRC)

  2008cited by this paper
• Mechanisms for copper acquisition, distribution and regulation.

  2008cited by this paper
• Systematic Design of a Targeted Organometallic Antitumour Drug in Pre-clinical Development

  2007cited by this paper
• Ethacrynic acid butyl-ester induces apoptosis in leukemia cells through a hydrogen peroxide mediated pathway independent of glutathione S-transferase P1-1 inhibition.

  2007cited by this paper
• Genetic determinants of cancer metastasis

  2007cited by this paper
• Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12.

  2007cited by this paper
• Organometallic Ruthenium Inhibitors of Glutathione‐S‐Transferase P1‐1 as Anticancer Drugs

  2007cited by this paper
• Broadening the clinical use of platinum drug–based chemotherapy with new analogues

  2007cited by this paper
• Ferrocifens and ferrocifenols as new potential weapons against breast cancer

  2007cited by this paper
• Ruthenium half-sandwich complexes bound to protein kinase Pim-1.

  2006cited by this paper
• Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma

  2006cited by this paper
• A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

  2006cited by this paper
• Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties.

  2006cited by this paper
• Drug discovery in the ubiquitin–proteasome system

  2006cited by this paper
• New approaches to molecular cancer therapeutics

  2006cited by this paper
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species

  2005cited by this paper
• Tuning of redox properties for the design of ruthenium anticancer drugs: part 2. Syntheses, crystal structures, and electrochemistry of potentially antitumor [Ru III/II Cl6-n(Azole)n]z(n = 3, 4, 6) complexes.

  2005cited by this paper
• Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.

  2005cited by this paper
• Augmentation of cisplatin sensitivity in cisplatin‐resistant human bladder cancer cells by modulating glutathione concentrations and glutathione‐related enzyme activities

  2005cited by this paper
• In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.

  2005cited by this paper
• GoldIII porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species.

  2005cited by this paper
• A Mass Spectrometric and Molecular Modelling Study of Cisplatin Binding to Transferrin

  2005cited by this paper
• Ruthenium anticancer drugs.

  2004cited by this paper
• A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  2004cited by this paper
• The proteasome: a suitable antineoplastic target

  2004cited by this paper
• Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.

  2004cited by this paper
• Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures?

  2003cited by this paper
• Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells.

  2003cited by this paper
• Characterization of cell death induced by ethacrynic acid in a human colon cancer cell line DLD‐1 and suppression by N‐acetyl‐l‐cysteine

  2003cited by this paper
• A Nucleotide-dependent Molecular Switch Controls ATP Binding at the C-terminal Domain of Hsp90

  2002cited by this paper
• Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

  2002cited by this paper
• Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties.

  2002cited by this paper
• Interactions of selected gold(III) complexes with calf thymus DNA.

  2001cited by this paper
• Proteasome Inhibition: a New Strategy in Cancer Treatment

  2000cited by this paper
• 1H N.M.R. investigations of the selective intramolecular migration of a platinum(II) complex from methionine sulfur to imidazole N 1 in N-acetylated L-methionyl-L-histidine

  2000cited by this paper
• Transferrin as a metal ion mediator.

  1999cited by this paper
• Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor.

  1998cited by this paper
• Improved understanding in platinium antitumour chemistry

  1996cited by this paper
• Platination Pathways for Reactions of Cisplatin with GG Single-Stranded and Double-Stranded Decanucleotides†

  1995cited by this paper
• Literature highlights—29

  1992cited by this paper
• Platinum-195 NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA

  1990cited by this paper
• Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines.

  1988cited by this paper
• Structural aspects of platinum anticancer drug interactions with DNA

  1987cited by this paper
• Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA.

  1980cited by this paper
• A Nucleotide-dependent Molecular Switch Controls Atp Binding at the C-terminal Domain of Hsp90 N-terminal Nucleotide Binding Unmasks a C-terminal Binding Pocket*

  year unknowncited by this paper

• Schiff base complexes derived from Trimethoprim

  2026cites this paper
• Half-Sandwich Organometallic Ir(III) and Ru(II) Compounds and their Interactions with Biomolecules.

  2025cites this paper
• Recent Advances in Schiff Base Coinage Metal Complexes as Anticancer Agents: A Comprehensive Review (2021–2025)

  2025cites this paper
• Synthesis, characterization, and anticancer potential of novel NHC ligands and their selenium complexes: a combined in vitro and in silico investigation

  2025cites this paper
• Advances of metallodrug-amyloid β aggregation inhibitors for therapeutic intervention in neurodegenerative diseases: Evaluation of their mechanistic insights and neurotoxicity

  2024cites this paper
• Silver and Gold Complexes with NHC-Ligands Derived from Caffeine: Catalytic and Pharmacological Activity

  2024cites this paper
• Synthesis and anticancer mechanisms of four novel platinum(II) 4'-substituted-2,2':6',2''-terpyridine complexes.

  2024cites this paper
• Ruthenium p-Cymene Complexes Incorporating Substituted Pyridine–Quinoline-Based Ligands: Synthesis, Characterization, and Cytotoxic Properties

  2024cites this paper
• New Ru(II)-p-cymene compounds bearing indomethacin and indomethacin-pyridineamide ligands: Synthesis, characterization, computational studies and investigation of their interactions with the human serum albumin

  2024cites this paper
• Interweaving catalysis and cancer using Ru- and Os-arene complexes to alter cellular redox state: A structure-activity relationship (SAR) review

  2023cites this paper
• Click-derived multifunctional metal complexes for diverse applications.

  2023cites this paper
• An overview of advancement of organoruthenium(II) complexes as prospective anticancer agents

  2023cites this paper
• Insights into the binding of half-sandwich phosphino Ir(III) and Ru(II) complexes to deoxyribonucleic acid, albumin and apo-transferrin: Experimental and theoretical investigation.

  2023cites this paper
• Study on the Multimodal Anticancer Mechanism of Ru(II)/Ir(III) Complexes Bearing a Poly(ADP-ribose) Polymerase 1 Inhibitor.

  2023cites this paper
• Synthesis and structural characterization of C,N-benzimidazole based ruthenium(II) complex with in vitro anticancer activity

  2023cites this paper
• DNA Binding and Cleavage, Stopped-Flow Kinetic, Mechanistic, and Molecular Docking Studies of Cationic Ruthenium(II) Nitrosyl Complexes Containing “NS4” Core

  2023cites this paper
• Diruthenium(II-III)-ibuprofen-loaded chitosan-based microparticles and nanoparticles systems: encapsulation, characterisation, anticancer activity of the nanoformulations against U87MG human glioma cells

  2023cites this paper
• Cell Death Mechanism of Organometallic Ruthenium(II) and Iridium(III) Arene Complexes on HepG2 and Vero Cells

  2023cites this paper
• Research Progress of Metal Anticancer Drugs

  2023cites this paper
• Recently Reported Ru-Metal Organic Coordination Complexes and Their Application (A Review)

  2022cites this paper
• Enriching Chemical Space of Bioactive Scaffolds by New Ring Systems: Benzazocines and Their Metal Complexes as Potential Anticancer Drugs

  2022cites this paper
• Synthesis, physicochemical studies, fluorescence behavior, and anticancer properties of transition metal complexes with the pyridyl ligand

  2022cites this paper
• Development of Mononuclear (Arene) Ruthenium Complexes as Anticancer Agents: A Review

  2022cites this paper
• Synthesis and cytotoxicity against tumor cells of pincer N-heterocyclic ligands and their transition metal complexes

  2021cites this paper
• Critical factors affecting the albumin binding of half-sandwich Ru(II) and Rh(III) complexes of 8-hydroxyquinolines and oligopyridines.

  2021cites this paper
• Evaluation of anticancer activity in vitro of a stable copper(I) complex with phosphine-peptide conjugate

  2021cites this paper
• Synthesis and catalytic applications of Ru(II)-phosphaurotropine complexes with the use of simple water-soluble Ru(II)-precursors

  2021cites this paper
• Pyridine derivative platinum complexes: Synthesis, molecular structure, DFT and initial anticancer activity studies

  2021cites this paper
• Structurally characterized copper-chrysin complexes display genotoxic and cytotoxic activity in human cells

  2021cites this paper
• Impact of the Metal Center and Leaving Group on the Anticancer Activity of Organometallic Complexes of Pyridine-2-carbothioamide †

  2021cites this paper
• A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway

  2020cites this paper
• Synthesis, Characterization, Cytotoxic Activity, and Metabolic Studies of Ruthenium(II) Polypyridyl Complexes Containing Flavonoid Ligands.

  2020cites this paper
• Octahedral Copper(II) Carboxylates with 1,10-Phenanthroline: Synthesis, Structural Characterization, DNA-Binding and Anti-Fungal Properties

  2020cites this paper
• Synthesis, physicochemical characterization and biological properties of two novel Cu(II) complexes based on natural products curcumin and quercetin.

  2020cites this paper
• Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells

  2020cites this paper
• Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.

  2020cites this paper
• Zwitterionic Ru(III) Complexes: Stability of Metal-Ligand Bond and Host-Guest Binding with Cucurbit[7]uril.

  2020cites this paper
• Ruthenium(iii) complexes containing thiazole-based ligands that modulate amyloid-β aggregation.

  2020cites this paper
• NAMI-A preferentially reacts with the Sp1 protein: understanding the anti-metastasis effect of the drug.

  2020cites this paper
• Transition metal complexes with 6,7-dichloro-5,8-quinolinedione as mitochondria-targeted anticancer agents

  2020cites this paper
• Physicochemical profile of Os (III) complexes with pyrazine derivatives: From solution behavior to DNA binding studies and biological assay

  2020cites this paper
• Exploring Serum Transferrin Regulation of Nonferric Metal Therapeutic Function and Toxicity

  2020cites this paper
• Frontiers of metal-coordinating drug design

  2020cites this paper
• pH dependence of the non-cooperative binding of Bi3+ to human apo-metallothionein 1A: kinetics, speciation, and stoichiometry.

  2020cites this paper
• Synthesis, characterization and biological activities of imidazo[1,2-a]pyridine based gold(III) metal complexes

  2019cites this paper
• Facile design and spectroscopic characterization of novel bio-inspired Quercetin-conjugated tetrakis (dimethylsulfoxide)dichlororuthenium(II) complex for enhanced anticancer properties

  2019cites this paper
• Ru(II)-thymine complex causes DNA damage and apoptotic cell death in human colon carcinoma HCT116 cells mediated by JNK/p38/ERK1/2 via a p53-independent signaling

  2019cites this paper
• Ruthenium Complexes Containing Heterocyclic Thioamidates Trigger Caspase-Mediated Apoptosis Through MAPK Signaling in Human Hepatocellular Carcinoma Cells

  2019cites this paper
• Highly Hydrophilic Gold Nanoparticles as Carrier for Anticancer Copper(I) Complexes: Loading and Release Studies for Biomedical Applications

  2019cites this paper
• Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity

  2019cites this paper
• NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry

  2019cites this paper
• Investigation of photo-activation on ruthenium(II)–arene complexes for the discovery of potential selective cytotoxic agents

  2019cites this paper
• Cytotoxic RuII-p-cymene complexes of an anthraimidazoledione: halide dependent solution stability, reactivity and resistance to hypoxia deactivation.

  2019cites this paper
• In-depth synthetic, physicochemical and in vitro biological investigation of a new ternary V(IV) antioxidant material based on curcumin.

  2019cites this paper
• A Ru(II)-p-cymene compound bearing naproxen-pyridineamide. Synthesis, spectroscopic studies, computational analysis and in vitro anticancer activity against lung cells compared to Ru(II)-p-cymene-naproxen and the corresponding drug ligands

  2019cites this paper
• In vitro and in vivo antitumor activities of three novel binuclear platinum(II) complexes with 4'-substituted-2,2':6',2″-terpyridine ligands.

  2019cites this paper
• Inhibition of telomerase activity and SK-OV-3/DDP cell apoptosis by rhodium(III) and iron(III) complexes with 4′-(3-thiophenecarboxaldehyde)-2,2′:6′,2″-terpyridine

  2019cites this paper
• Phosphine–copper(I) complexes as anticancer agents: design, synthesis, and physicochemical characterization. Part I

  2019cites this paper
• Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action.

  2019cites this paper
• Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: starting from the classical paradigm to targeting multiple strategies

  2019cites this paper
• A new class of platinum(II) complexes with the phosphine ligand pta which show potent anticancer activity

  2018cites this paper
• Synthesis, cytotoxicity and anti-metastatic properties of new pyridyl–thiazole arene ruthenium(II) complexes

  2018cites this paper
• Organometallic catalysis in biological media and living settings

  2018cites this paper
• Novel class of mononuclear 2-methoxy-4-chromanones ligated Cu (II), Zn (II), Ni (II) complexes: synthesis, characterisation and biological studies

  2018cites this paper
• RAPTA complexes containing N‐substituted Tetrazole scaffolds: Synthesis, characterization and Antiproliferative activity

  2018cites this paper
• Arene Ruthenium Complexes in Supramolecular Chemistry

  2018cites this paper
• Synthesis, characterization and cytotoxicity of arene-ruthenium(ii) complexes with acylpyrazolones functionalized with aromatic groups in the acyl moiety.

  2018cites this paper
• Antitumorski potencijal organometalnih kompleksa rutenija

  2018cites this paper
• Ruthenium(ii) arene NSAID complexes: inhibition of cyclooxygenase and antiproliferative activity against cancer cell lines.

  2018cites this paper
• Cellular Pharmacology of Palladinum(III) Hematoporphyrin IX Complexes: Solution Stability, Antineoplastic and Apoptogenic Activity, DNA Binding, and Processing of DNA-Adducts

  2018cites this paper
• Synthesis and characterization of kaempferol-based ruthenium (II) complex: A facile approach for superior anticancer application.

  2018cites this paper
• Selective C8-Metalation of Purine Nucleosides via Oxidative Addition

  2018cites this paper
• Binding of Organometallic Ruthenium Anticancer Complexes to DNA: Thermodynamic Base and Sequence Selectivity

  2018cites this paper
• Dual-functional cyclometalated iridium imine NHC complexes: highly potent anticancer and antimetastatic agents

  2018cites this paper
• Synthesis, in vitro cytotoxicity, and structure-activity relationships (SAR) of multidentate oxidovanadium(iv) complexes as anticancer agents.

  2018cites this paper
• The Anticancer Activities of Some Nitrogen Donor Ligands Containing bis-Pyrazole, Bipyridine, and Phenanthroline Moiety Using Docking Methods

  2018cites this paper
• Title Ligand substitutions between ruthenium – cymene compounds can control protein versus DNA targeting and anticancer activity

  2018cites this paper
• Nucleobases Having M-C Bonds: An Emerging Bio-Organometallic Field: Nucleobases Having M-C Bonds: An Emerging Bio-Organometallic Field

  2018cites this paper
• Through-Space Paramagnetic NMR Effects in Host-Guest Complexes: Potential Ruthenium(III) Metallodrugs with Macrocyclic Carriers.

  2018cites this paper
• BIOLOGICAL ACTIVE COMPLEXES OF PALLADIUM(II) WITH AROMATIC N-HETEROCYCLES (Review)

  2018cites this paper
• Palladium complexes of bidentate pyridine N‐heterocyclic carbenes: Optical resolution, antimicrobial and cytotoxicity studies

  2018cites this paper
• Multi-Target Metal-Based Anticancer Agents.

  2017cites this paper
• Conformational and structural diversity of iridium dimethyl sulfoxide complexes

  2017cites this paper
• New palladium(II) formamidine complexes: Preparation, characterization, theoretical calculations and cytotoxic activity

  2017cites this paper
• An omics perspective to the molecular mechanisms of anticancer metallo-drugs in the computational microscope era

  2017cites this paper
• Aspirin-inspired organometallic compounds: Structural characterization and cytotoxicity

  2017cites this paper
• Discovery of a series of ruthenium(II) derivatives with α-dicarbonylmonoxime as novel inhibitors of cancer cells invasion and metastasis

  2017cites this paper
• Effect of cisplatin on triple negative breast cancer cells

  2017cites this paper
• Theoretical Insight into the Medicinal World of Organometallics: Macro versus Nano

  2017cites this paper
• Biohybrid Membrane Systems for Testing Molecules and Stem Cell Therapy in Neuronal Tissue Engineering.

  2017cites this paper
• Ternary and binary copper(II) complexes: synthesis, characterization, ROS-inductive, proteasome inhibitory, and anticancer properties

  2017cites this paper
• Regioselective C8-metalation of N-phosphine tethered adenine derivatives via C8-H activation.

  2017cites this paper
• First Dicationic Ruthenium(II)-arene Curcumin Complexes containing methylated PTA: Synthesis, Structure and Cytotoxicity

  2017cites this paper
• Coordination compounds of 4,5,6,7-tetrahydro-1H-indazole with Cu(II), Co(II) and Ag(I): structural, antimicrobial, antioxidant and enzyme inhibition studies

  2017cites this paper
• Theoretical study on the antitumor properties of Ru(II) complexes containing 2-pyridyl, 2-pyridine-4-carboxylic acid ligands

  2017cites this paper
• Organoruthenium(II) compounds with pyridyl benzoxazole/benzthiazole moiety: studies on DNA/protein binding and enzyme mimetic activities

  2017cites this paper
• Synthesis and structure of new binuclear ruthenium(II) arene benzil bis(benzoylhydrazone) complexes: investigation on antiproliferative activity and apoptosis induction

  2017cites this paper
• Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors

  2017cites this paper
• Thirty Years of the Drug Candidate NAMI‐A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective

  2017cites this paper
• DNA-binding, molecular docking studies and biological activity studies of ruthenium(II) polypyridyl complexes

  2017cites this paper